We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · March 25, 2021

High-Dose vs Standard-Dose Twice-Daily Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy for Patients With Limited Stage Small-Cell Lung Cancer: An Open-Label, Randomised, Phase 2 Trial
Lancet Oncol 2021 Mar 01;22(3)321-331, BH Grønberg, KT Killingberg, Ø Fløtten, OT Brustugun, K Hornslien, T Madebo, SW Langer, T Schytte, J Nyman, S Risum, G Tsakonas, J Engleson, TO Halvorsen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading